帕瑞昔布钠治疗肝癌化疗栓塞术后疼痛的临床研究.docVIP

精品论文 参考文献 帕瑞昔布钠治疗肝癌化疗栓塞术后疼痛的临床研究 周官辉 孙军辉 张岳林 聂春晖 周坦洋 朱统寅 王宝泉 陈圣群 陈黎明 郑树森（通讯作者） 　　（浙江大学医学院附属第一医院肝胆胰介入中心 浙江杭州 310003） 　　【摘要】方法：比较帕瑞昔布钠与双氯芬酸钠治疗肝癌化疗栓塞术后疼痛的临床疗效及不良反应。方法：对80例肝癌化疗栓塞术后患者，随机分为两组，分别于术后使用帕瑞昔布钠及双氯芬酸钠进行治疗，帕瑞昔布钠剂量为40mg bid、双氯芬酸钠剂量为75mg qd。治疗前后分别记录疼痛视觉模拟评分(VAS)，记录恶心、呕吐、便秘等不良反应，比较两组疗效与不良反应的发生率。结果：帕瑞昔布钠组与双氯芬酸钠组的中重度疼痛发生率分别为12.5%与35%（chi;2=5.59，Plt;0.05）及其不良反应发生率低，主要有恶心、呕吐等，未发现有明显严重不良反应， 两组不良反应的发生率无显著差异（chi;2=0.20，Pgt;0.05）。结论：帕瑞昔布钠总体疗效均优于双氯芬酸钠，且副作用未见明显增加， 更适合用于肝癌化疗栓塞术后疼痛的控制和治疗。 　　【关键词】帕瑞昔布钠；肝癌；化疗栓塞；止痛 　　【中图分类号】R97 【文献标识码】A 【文章编号】1007-8231（2015）06-0035-03 　　The clinical study on the curative effect of parecoxib sodium in pain treatment after chemoembolization for liver cancer 　　【Abstract】Objective Comparison of parecoxib sodium and diclofenac sodium in the treatment of liver cancer chemoembolization pain in clinical efficacy and adverse reaction .Methods 80 cases of treament of liver cancer chemoembolization pain were randomly divided into two groups , respectively , after the use of parecoxib sodium and diclofenac sodium for treatment, parecoxib sodium dose 40 mg bid, diclofenac sodium dose 50 mg qd. Clinical efficacy were observed before and after treatment, recording nausea, vomiting , constipation and other adverse reactions, compared the efficacy and the incidence of adverse reactions . Results The sodium moderate to severe pain rates in parecoxib sodium and diclofenac groups were 12.5% and 35%(chi;2=5.59, Plt;0.05), and its lower incidence of adverse reactions, mainly nausea, vomiting and found no significant serious adverse reactions. The incidence of adverse reactions was no significant difference between the two groups (chi;2=0.20, Pgt;0.05). Conclusion Parecoxib sodium delivery methods are superior efficacy of diclofenac sodium , and no more effects and its more suitable for liver cancer chemoembolization for treatment of postoperative pain. 　　【Key words】Parecoxib sodium;Liver cancer;TACE;Pain treatment 　　经导管肝动脉化疗栓塞术(TACE)目前已